Synonym
Kebuzone; ketophenylbutazone, RN 0308507; Chebutan; Chepirol; Chetazolidin; Chetil; Copirene; Hichillos; Kebuzone; Kebuzonum; Ketason; Ketazone; Recheton
IUPAC/Chemical Name
4-(3-oxobutyl)-1,2-di(phenyl)pyrazolidine-3,5-dione
InChi Key
LGYTZKPVOAIUKX-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3
SMILES Code
O=C(C1CCC(C)=O)N(C2=CC=CC=C2)N(C3=CC=CC=C3)C1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Kebuzone is a non-steroidal anti-inflammatory substance that may be studied in inflammatory diseases such as thrombophlebitis and rheumatoid arthritis.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
322.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Senra H, Vieira CR, Nicholls EG, Leal I. Depression and experience of vision loss in group of adults in rehabilitation setting: mixed-methods pilot study. J Rehabil Res Dev. 2013;50(9):1301-14. doi: 10.1682/JRRD.2012.08.0138. PubMed PMID: 24458969.
2: Maurer HH, Tauvel FX, Kraemer T. Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. J Anal Toxicol. 2001 May-Jun;25(4):237-44. PubMed PMID: 11386636.
3: Zhivkova ZD, Russeva VN. Binding of kebuzone to human serum albumin studied by high performance liquid affinity chromatography. Arzneimittelforschung. 2000 Mar;50(3):272-5. PubMed PMID: 10758780.
4: Sochor J, Klimes J, Sedlácek J. [HPLC analysis of nonsteroidal antirheumatic agents in biological materials. III. Pyrazolidinediones]. Ceska Slov Farm. 1998 May;47(3):128-33. Czech. PubMed PMID: 9650370.
5: Klimes J, Sochor J, Sedlacek J. Solid-phase extraction and HPLC analysis of kebuzone and its metabolites in blood. Pharmazie. 1996 Sep;51(9):651-3. PubMed PMID: 8878255.
6: Pospísilová M, Jokl V, Polásek M, Mokrá J. Determination of some non-steroid anti-inflammatory drugs by capillary isotachophoresis. J Pharm Biomed Anal. 1995 Aug;13(9):1147-52. PubMed PMID: 8573641.
7: Rahman MH, Yamasaki K, Shin YH, Lin CC, Otagiri M. Characterization of high affinity binding sites of non-steroidal anti-inflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull. 1993 Nov;16(11):1169-74. PubMed PMID: 8312878.
8: Varga L, Asztalos L. [Nicolau syndrome after ketazon injection]. Orv Hetil. 1990 May 27;131(21):1143-6. Hungarian. PubMed PMID: 2242120.
9: Neuschl J. [Relation of nonsteroidal anti-inflammatory agents and reserpine to calcium homeostasis]. Cesk Farm. 1987 Sep;36(7):312-6. Slovak. PubMed PMID: 3664648.
10: Rohozková D, Votrubová L, Tesárek B, Trnavský K. [Levels of proteolytic enzymes in experimental osteoarthrosis controlled by antirheumatic agents]. Bratisl Lek Listy. 1986 Feb;85(2):146-51. Czech. PubMed PMID: 3754175.
11: Heidelmann G, Porst H, Liebscher K. [Ketazone hepatosis--a possibility for the development of secondary hypouricemia]. Z Arztl Fortbild (Jena). 1986;80(1):17-8. German. PubMed PMID: 3754366.
12: Vyskocil A, Tusl M, Chmelar V. The effect of pretreatment with ketazon on the inflammatory changes in lung and concentration of corticosterone in serum of rats after nitrogen dioxide inhalation. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1986;29(4-5):511-6. PubMed PMID: 3481654.
13: Neuschl J, Kohút A, Nicák A. [The effect of calcium chloride on the ulcerogenic effect of ketophenylbutazone in relation to the calcium content of the gastric wall]. Bratisl Lek Listy. 1985 Dec;84(6):659-63. Slovak. PubMed PMID: 3841499.
14: Kunze KD, Porst H, Tschöpel L. [Morphology and pathogenesis of liver injury produced by dihydralazine , propranolol and ketophenylbutazone]. Zentralbl Allg Pathol. 1985;130(6):509-18. German. PubMed PMID: 3841742.
15: Rerábková L. [Damage to skeletal muscles by intramuscular administration of anti-inflammatory agents of the pyrazolidine type]. Sb Lek. 1983 Jun;85(6):161-6. Czech. PubMed PMID: 6688477.
16: Heidelmann G, Burck G, Dauterstedt W, Heinrich JJ, Ohlmer R. [Indications for and methods of allopurinol-benzbromarone combination therapy in the treatment of hyperuricemic metabolic disorders]. Z Arztl Fortbild (Jena). 1982 Mar 1;76(5):177-81. German. PubMed PMID: 6896252.
17: Poctová M, Kakác B. [Determination of azobenzene and hydrazobenzene in Ketazon dosage forms]. Cesk Farm. 1981 Jun;30(5):159-61. Czech. PubMed PMID: 6895348.
18: Cepelák V, Cepeláková H, Brůnová B, Kuchar M, Roubal Z. Pyrazolidine derivatives: a comparative study of their effects on platelet aggregation. Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):839-48. PubMed PMID: 94876.
19: Bachratá M, Bezáková Z, Knazko L, Subert J. The use of borohydrides of alkaline metals in the volumetric analysis of medicaments. Pharmazie. 1977 Jul 7;32(7):398-401. PubMed PMID: 909904.
20: Mayer J, Král A. [An attempt to influence the postoperative course by Ketazon Spofa. (Clinical trial)]. Cesk Stomatol. 1967 Sep;67(5):361-5. Czech. PubMed PMID: 16094957.
